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Summary The optimal treatment strategy for patients with asymptomatic carotid artery
stenosis (ACS) is still a matter of debate. Based on a simplistic view, all stenosed vessels should
be cleaned, and the earlier the better. Due to the improvements of medical management instenosis;
Medical treatment;
Carotid
endarterectomy;
patients with high-grade ACS, there is uncertainty as how to best manage these patients. Con-
sequently, the cost-effectiveness of CEA in patients with ACS has been questioned. Therefore,
the question arises how best medical treatment changes the risk of stroke in patients with ACS.
This overview discussed the therapeutic options for ACS from a neurological point of view.
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symptomatic signiﬁcant (>50%) carotid stenosis (ACS) is
frequent ﬁnding in the aging population. The preva-
ence of moderate stenosis (50—70%) increases from 3.6%
or those <70 years to 9.3% in those 70 years and
bove. The prevalence of severe (70—99%) stenosis is 1.7%
1].
The optimal treatment strategy for patients with ACS
s still a matter of debate. Based on a simplistic view,
ll stenosed vessels should be cleaned, the earlier the
etter. This is the rationale behind an approach to treat
ven asymptomatic patients. The therapeutic effectiveness
f a carotid endarterectomy (CEA) in high-grade ACS has
Openeen demonstrated in large trials, but the number needed
o treat (NNT) is high. On the other hand, CEA is not
ree of complications, the frequency of which depends on
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Open access under CC BY-NC-ND license.enter and surgeon. Unlike symptomatic carotid stenosis,
CS carries a low risk for ipsilateral stroke [2]. The data
rom CEA trials are more than 20 years old and medical
reatment of risk factors (e.g. statins, ACE inhibitors) has
hanged considerably. In the current best medical treat-
ent (BMT) approach the risk of stroke is therefore even
maller and the number needed to treat by CEA increases.
onsequently, the cost-effectiveness of CEA in patients with
CS has been questioned [3]. Recently carotid artery stent-
ng (CAS) became a new ‘‘bloodless’’ option. Unfortunately,
he comparison between CEA and CAS resulted in conﬂicting
onclusions.
This overview discussed the therapeutic options for ACS
rom a neurological point of view.
EA vs. CAS vs. BMT
hether CEA and CAS are comparable treatment options in
s under CC BY-NC-ND license.CS or whether a revascularization is better than BMT is cur-
ently investigated in the ongoing SPACE-II trial [4], including
atients with >70% carotid stenosis that were randomized
nto 3 arms (CEA, CAS, BMT) as well as in the ACST-2 trial
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that plans to recruit 5000 patients and follow them up for
at least 5 years [5].
CEA vs. CAS
The CREST (‘‘carotid revascularization endarterectomy vs.
stenting trial’’) and SAPPHIRE (‘‘stenting and angioplasty
with protection in patients at high risk for endarterectomy’’)
are 2 randomized trials comparing CEA and CAS.
The North-American CREST trial showed a comparable
30-day complication rate for CEA (3.7%) and PTA (3.1%) in
the subgroup of patients with ACS [6]. The 4-year risk (any
peri-procedural stroke or death, ipsilateral post-procedural
stroke) was increased in CAS (4.5%) as compared to CEA
(2.7%). However, this difference was not statistically signif-
icant (RR 1.86; 95% CI 0.95—3.66, p = 0.07) but CREST was
not powered for subgroup analysis.
In the SAPPHIRE study, the 30-day risk of MI, stroke, or
death was 5.4% for CAS, and 10.2% for CEA (not signiﬁcantly
different). Of note, these complication rates are higher for
asymptomatic individuals compared with symptomatic par-
ticipants within the same trial, and probably exceed the
threshold of 3% [7]. For this reason, a persistent criticism
of this trial remains that the enrolled patients should not
have undergone revascularization at all, given the trial’s
perioperative complication rates [8].
Current practice of CAS and CEA in the US for asymp-
tomatic stenosis was recently examined, and in-hospital
complication rates were presented [9]. CAS was associated
with increased odds of stroke or death (OR 1.28, 95% CI
1.03—1.58).
CAS vs. BMT
Neither SAPPHIRE nor CREST address the question now posed
by improvements in BMT, namely whether patients with ACS
should undergo any revascularization procedure.
CEA vs. BMT
Two trials, ACAS (‘‘asymptomatic carotid atherosclerosis
study’’) and ACST (‘‘asymptomatic carotid surgery trial’’),
randomized asymptomatic patients with angiographically
conﬁrmed stenosis >60% (ACAS) or stenosis >50% on ultra-
sonography studies (ACST) to CEA vs. a BMT group (or
BMT/deferred CEA in the case of ACST). Despite slight dif-
ferences in entry criteria and analysis, overall outcomes
were fairly similar, with a slightly less than 5% decrease in
stroke/death over 5 years. The larger number of patients
enrolled into ACST and its longer follow-up period provide
a more speciﬁc understanding of the modest gains of CEA
vs. BMT, as follows: (1) of the 4.1% absolute reduction in
stroke/death over 5 years, only half of this beneﬁt came
from preventing disabling strokes/death (a net gain < 0.5%
per year); (2) after 5 years, no further beneﬁt accrues, with
a net gain of only 4.6% at 10 years (CEA vs. BMT lines parallel
each other after 5 years); (3) no beneﬁt exists for patients
older than 75 years; (4) women derive less beneﬁt (reach-
ing statistical signiﬁcance only at 10 years); and (5) patients
on a regimen of lipid-lowering agents have less beneﬁt [8].
A
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s113
iven the underwhelming gains achieved by CEA in asymp-
omatic patients relative to symptomatic patients, beneﬁt
as critically dependent on an extremely low perioperative
omplication rate, with 3% set as the threshold margin for
erioperative stroke/death.
However, signiﬁcant improvements in BMT have occurred
ver time, especially in the use of lipid-lowering drugs such
s statins, which were used in only 10% of patients in the
CST at trial initiation and in 80% at 10-year follow-up.
he SMART (‘‘second manifestation of arterial disease’’)
rial showed that in patients with an ACS >50% the annual
troke risk was only 0.8% even in patients with an increased
ascular risk [10]. Marquard et al. [11] demonstrated in
population-based trial from Oxford that a well-treated
atient with ACS >50% has an annual risk of ipsilateral stroke
f only 0.34%. Recent data from the asymptomatic arm of
he CREST trial revealed a 30-day peri-procedural risk of
.1% for TEA and an ipsilateral 4-year stroke risk (exclud-
ng the peri-procedural period) of 1.3% [12]. Similar results
ere obtained from an analysis of registry data from the US
hich showed, that a beneﬁt of CEA (if any) may be seen only
fter several years [13]. A recent meta-analysis [3] including
1 studies with 3724 patients with ACS done between 1983
nd 2003 revealed that rates of ipsilateral and any-territory
troke and TIA, with medical intervention alone, have fallen
igniﬁcantly since the mid-1980s and show a gradual reduc-
ion in the average annual risk from approximately 2.5% in
hemid-1980s to approximately 1% by 2008, with recent esti-
ates overlapping those of operated patients in randomized
rials. Additionally, current medical intervention alone was
stimated at least 3—8 times more cost-effective [14].
CS is associated with an increased overall
ascular risk
he ACS patient has an increased overall vascular risk: In the
MART study the MI risk was 3.6% per year and thus 4 times
igher than the stroke risk [10]. The PRECORIS study [15]
ssessed the prevalence of ≥50% asymptomatic coronary
rtery disease (CAD) in 274 patients with ischemic stroke
r TIA using cardiac CTA. The prevalence of ≥50% asymp-
omatic CAD was 18% Asymptomatic CAD was independently
ssociated with traditional risk factors assessed individu-
lly and through the Framingham Risk Score (OR 2.6; 95%
I 1.0—7.6 for a 10-year risk of coronary heart disease of
0—19%; and OR 7.3; 95% CI 2.8 to 19.1 for a 10-year risk
f coronary heart disease ≥20%), the presence of at least
ne ≥50% cervicocephalic artery stenosis (OR, 4.0 95% CI
.4—11.2) and other factor including alcohol consumption
nd ankle brachial index. In every category of Framingham
isk, prevalence of CAD was strongly related to the degree
f cervicocephalic stenosis (Fig. 1). Therefore, detection of
n ACS should lead to a cardiac workup and to an optimal
reatment of vascular risk factors [2].
isk stratiﬁcationsymptomatic embolization
everal methods to identify such a high-risk group have been
uggested, including ultrasonic detection of asymptomatic
114
Figure 1 Prevalence of asymptomatic CAD according to sever-
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•ty of cervicocephalic stenosis and Framingham risk score
FRS)-predicted 10-year CHD risk group. According to [15].
mbolization. If clinical embolism is a good predictor of
he subsequent stroke risk, asymptomatic cerebral emboli
ight also predict clinical stroke risk [16]. Transcranial
oppler ultrasound (TCD) is a non-invasive technique that
an be used to detect circulating emboli. Several studies
valuated the association between detection of embolic sig-
als and new ischemic events in patients with ACS [17—19]
nd reported different results. Recently a large prospec-
ive and multi-center study (ACES, asymptomatic Carotid
mboli Study) evaluated the relationship between asymp-
omatic emboli and stroke risk in 467 patients with an ACS
f at least 70% [16]. The detection of emboli was associated
ith an increased risk for ipsilateral TIA and stroke (HR 2.54,
5% CI 1.2—5.36) and in particular for ipsilateral stroke (HR
.57, 95% CI 1.61—19.32) during 2 years of follow-up even
fter adjusting for antiplatelet therapy, degree of stenosis,
nd other risk factors. The absolute annual risk of ipsilat-
ral stroke or TIA between baseline and 2 years was 7.13%
n patients with embolic signals and 3.04% in those with-
ut, and for ipsilateral stroke was 3.62% in patients with
mbolic signals and 0.70% in those without. The authors per-
ormed a meta-analysis with all studies available including
144 patients. The hazard ratio for the risk of ipsilateral
troke for those with embolic signals compared with those
ithout was 6.63 (95% CI 2.85—15.44) with no heterogeneity
etween studies (p = 0.33).
etection of echolucent plaque using ultrasound
ore recently, data from ACES demonstrated that plaque
orphology assessed using a simple visual rating scale pre-
icts ipsilateral stroke in ACS [20]. 435 subjects with ACS
70% were included and followed-up for 2 years. A 4-point
isual rating scale was applied to the plaques and they
ere classiﬁed as echolucent (37.7%) or echogenic. Plaque
cholucency at baseline was associated with an increased
isk of ipsilateral stroke alone (HR 6.43, 95% CI 1.36—30.44).
combination of plaque echolucency and ES positivity at
aseline was associated with an increased risk of ipsilateral
troke alone (HR 10.61, 95% CI 2.98—37.82). The combina-
ion of ES detection and plaque morphology allows a greater
RD. Sander, M. Valet
rediction than either measure alone and identiﬁes a high-
isk group with an annual stroke risk of 8%, and a low-risk
roup with a risk of <1% per year. These data show that the
ombination of 2 measures of plaque instability may identify
high-risk group of patients with ACS that may beneﬁt from
CEA.
agnetic resonance imaging (MRI) of plaque
RI is a non-invasive method of plaque measurement that
oes not involve ionizing radiation. Examination of plaque
nder different contrast weighting (black blood: T1, T2, pro-
on density-weightings, and magnetization prepared rapid
radient echocardiography or bright blood: time of ﬂight)
llows characterization of individual plaque components,
ncluding lipid-rich necrotic core, ﬁbrous cap status, hem-
rrhage, and calciﬁcation [21]. A few small prospective
tudies have been done to investigate characteristics of
arotid artery plaque on MRI that are associated with disease
rogression and future cardiovascular events. One study
22] examined patients with symptomatic and asymptomatic
arotid disease to determine whether ﬁbrous cap thinning or
upture as identiﬁed on MRI were associated with a history
f recent transient ischemic attack or stroke. When com-
ared with patients with a thick ﬁbrous cap, patients with a
uptured cap were 23 times more likely to have had a recent
ransient ischemic attack or stroke. An increased risk of ipsi-
ateral cerebrovascular events has also been reported over
mean follow-up period of 38.2 months in asymptomatic
atients who had 50—79% carotid stenosis and the presence
f a thin or ruptured ﬁbrous cap, intraplaque hemorrhage,
r a larger lipid-rich necrotic core [23]. At this time there
re no published prospective population data to evaluate
he role of MRI ﬁndings in risk assessment of asymptomatic
dults. A number of large-scale studies are ongoing [21].
onclusion
Patients with ACS have a high overall vascular risk. A car-
diac workup and an optimal treatment of vascular risk
factors should be done.
CEA is an evidenced-based therapeutic option. However,
most data come from the 90s of the last century. Actually,
the available data for CAS are not sufﬁcient to judge the
role of CAS as compared to TEA and BMT.
BMT has led to a signiﬁcant reduction of stroke risk (<1%
per year) in patients with ACS, Therefore, the indication
or a CEA should be done with restraint and based on life
expectancy, sex, and comorbidity.
Detection of echolucent plaques using duplex ultrasonog-
raphy, embolic signals using TCD or unstable plaques using
MRI criteria identiﬁes high-risk patients for stroke and
could be helpful for the decision whether a CEA should
be done. Otherwise, aggressive medical therapy of risk
factors is recommended.eferences
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